Description

Fludrocortisone Acetate Tablets contain 0.1?mg fludrocortisone acetate— a synthetic fluorinated derivative of cortisol with potent mineralocorticoid activity. It acts by promoting sodium retention, increasing vascular responsiveness to catecholamines, and expanding plasma volume. Widely applied in clinical treatment of adrenal insufficiency disease (e.g., salt-wasting congenital adrenal hyperplasia and Addison’s disease), in research it is used to model prolonged sodium retention, fluid regulation, blood pressure dynamics, and electrolyte homeostasis. Manufactured by Haupt Pharma Amareg GmbH under Chinese approval HJ20240027. Supplied in bottles of 100 tablets. For laboratory/research use only.

Product Specifications

Mechanism of Action & Research Applications

Fludrocortisone Acetate mimics and enhances endogenous mineralocorticoid activity by binding mineralocorticoid receptors in renal collecting ducts. It promotes sodium and water retention, potassium excretion, and enhances vascular volume and blood pressure responsiveness. This mechanism makes it an important research tool for studying salt-wasting conditions, orthostatic hypotension models, electrolyte regulation, fluid volume experiments, and adrenal insufficiency correction in preclinical settings.

Side Effects (For Reference Only in Research Models)

Research analogs may show elevated blood pressure, edema, hypokalemia, weight gain, headache, insomnia, and swelling. Overdose or prolonged use may lead to mineralocorticoid excess, hypertension, congestive heart failure, and electrolyte disturbances. These effects should inform experimental dose planning and monitoring.

Disclaimer

Fludrocortisone Acetate Tablets are strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.